Clinical Trial

A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated March 10, 2026 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to learn the safety, tolerability, pharmacokinetic characteristics and efficacy of FC084CSA in combination with Tislelizumab in patients with advanced malignant solid tumors.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-07-08; most recent amendment 2026-03-08.
Status change: Not Yet Recruiting → Recruiting 2025-08-06
Trial Details
NCT Number NCT06499350
Lead Sponsor FindCure Biosciences (ZhongShan) Co., Ltd.
Conditions Advanced Malignant Solid Tumors
Enrollment 33 participants
Start Date 2024-11-13
Primary Completion 2026-07-01 (estimated)
Study Completion 2026-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-10